Filing Analysis
KORU Medical Systems, Inc. amended its By-laws to specify that the removal of a director requires an affirmative vote from shareholders holding a majority of outstanding shares. This change aligns the company's bylaws with Delaware General Corporation Law.
🚩 Red Flags
- None identified; the filing explicitly states there is no current intent to use this provision for removal of directors.
📋 Key Facts
- Effective date of amendment: August 13, 2026.
- Amendment to Section 3.05 of the Company’s Amended and Restated By-laws.
- The authority to remove a director is now vested exclusively in shareholders holding a majority of outstanding shares.
- Board stated they have no current intention or agreement to remove any director.
KORU Medical Systems, Inc. announced its second fiscal quarter financial results for the period ended June 30, 2026, and provided updated financial guidance for the full fiscal year.
🚩 Red Flags
- The filing contains a likely clerical error/discrepancy where it mentions updating guidance for the fiscal year ended December 31, 2025, despite reporting results for June 2026.
📋 Key Facts
- Reporting date: August 5, 2026
- Period covered: Second fiscal quarter ended June 30, 2026
- The company issued an update to its financial guidance for the fiscal year ending December 31, 2025 (Note: potential typo in filing text regarding years)
- Management is utilizing non-GAAP measures including 'adjusted EBITDA' and 'adjusted diluted EPS'
KORU Medical Systems entered into an amendment to its Manufacturing and Supply Agreement with Command Medical Products, LLC. The amendment extends the agreement term through 2031 and introduces requirements for a second manufacturing site by year-end 2027.
🚩 Red Flags
- Dependency on a single supplier (Command) for a limited set of products via exclusivity clause.
📋 Key Facts
- Amendment No. 1 to the Amended and Restated Manufacturing and Supply Agreement was effective June 24, 2026.
- The agreement term is extended until December 31, 2031, with automatic one-year renewals.
- Command Medical Products must qualify a second manufacturing site by December 31, 2027; failure to do so grants KORU termination rights after a 30-day cure period.
- The amendment modifies pricing, payment terms, and annual price adjustments.
- Command is established as the exclusive manufacturer for a limited set of products.
- Non-competition provisions were removed from the agreement.
KORU Medical Systems, Inc. reported the voting results from its 2026 Annual Meeting of Shareholders held on May 19, 2026. Shareholders approved all proposals, including the election of seven directors, an amendment to the 2024 Omnibus Equity Incentive Plan, and the ratification of the company's independent auditor.
📋 Key Facts
- The 2026 Annual Meeting of Shareholders was held on May 19, 2026, with 36,678,784 total shares voted.
- Seven directors were elected to the Board: R. John Fletcher, Robert A. Cascella, Donna French, Joseph M. Manko, Jr., Shahriar (Shar) Matin, Linda Tharby, and Edward Wholihan.
- Shareholders approved an amendment to the 2024 Omnibus Equity Incentive Plan to increase the available number of shares with 25,018,973 votes in favor.
- Cherry Bekaert LLP was ratified as the independent registered public accountants for the 2026 fiscal year with 36,500,510 votes in favor.
KORU Medical Systems reported its financial results for the first quarter ended March 31, 2026, and reaffirmed its financial guidance for the full fiscal year. The company utilized non-GAAP metrics, including Adjusted EBITDA, to provide additional insight into its operating performance.
📋 Key Facts
- Financial results released for the first fiscal quarter ended March 31, 2026.
- Management reiterated financial guidance for the fiscal year ending December 31, 2026.
- Non-GAAP measures (Adjusted EBITDA and Adjusted Diluted EPS) exclude depreciation, amortization, interest, litigation expense, and stock-based compensation.
- A conference call was scheduled for May 6, 2026, at 4:30pm ET to discuss results.
KORU Medical Systems entered into an amendment with HSBC Ventures to extend the maturity and improve the terms of its $10 million credit facility. The amendment extends the revolver and term loan maturities, lowers the interest rate floor, and relaxes financial covenants.
📋 Key Facts
- Amendment to Loan and Security Agreement with HSBC Ventures USA Inc. effective March 30, 2026.
- Revolving credit facility of $5,000,000 maturity extended from December 31, 2026, to March 30, 2028.
- Term loan facility of $5,000,000 maturity extended from December 1, 2028, to December 1, 2029.
- Interest rate floor reduced from 6.50% to 5.50% for both facilities.
- Adjusted quick ratio covenant removed; replaced with a 12-month liquidity covenant triggered only if the Revolver is drawn.
- The Company has not yet drawn on the Credit Facility.
KORU Medical Systems announced a CEO succession plan where current CEO Linda Tharby will retire on June 30, 2026, and be succeeded by Adam Kalbermatten on July 1, 2026. The transition includes a structured advisory period for Ms. Tharby through the end of 2026 and a new employment agreement for Mr. Kalbermatten with performance-based incentives.
📋 Key Facts
- Linda Tharby to retire as CEO effective June 30, 2026, and will serve as a non-executive advisory employee through December 31, 2026.
- Adam Kalbermatten appointed President effective March 15, 2026, and will become CEO on July 1, 2026.
- Mr. Kalbermatten's base salary will increase from $450,000 to $525,000 upon assuming the CEO role.
- Mr. Kalbermatten will receive a one-time 'Promotion PSU' award valued at $1.25 million, weighted 75% toward revenue growth and 25% toward market capitalization objectives.
- Ms. Tharby will receive 50% of her base salary during her advisory period and retains specific equity vesting rights through 2028.
- Ms. Tharby will resign from the Board of Directors effective December 31, 2026, with Mr. Kalbermatten expected to join the Board on January 1, 2027.
KORU Medical Systems announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided financial guidance for the 2026 fiscal year.
📋 Key Facts
- Financial results reported for Q4 and full year 2025 on March 12, 2026.
- Company provided forward-looking financial guidance for the fiscal year ending December 31, 2026.
- Management utilized non-GAAP financial measures including 'adjusted EBITDA' and 'adjusted diluted EPS'.
- A conference call was scheduled for March 12, 2026, at 4:30pm Eastern Time to discuss results.
KORU Medical Systems, Inc. has amended and restated its Bylaws to comply with new SEC rules regarding universal proxy cards and to update procedural mechanics for stockholder nominations and proposals.
📋 Key Facts
- The Board of Directors unanimously adopted the resolution on February 5, 2026.
- Amendments include enhanced disclosure requirements for nominating or proposing stockholders and nominees.
- Changes address compliance with Rule 14a-19 under the Securities Exchange Act of 1934.
- The update includes changes to advance notice deadlines for director nominations in specific circumstances.
KORU Medical Systems, Inc. issued a press release announcing preliminary financial results for the fiscal quarter and year ended December 31, 2025.
📋 Key Facts
- Announcement date: January 12, 2026
- Reporting period: Fiscal quarter and year ended December 31, 2025
- Results are preliminary estimates and subject to change pending final closing and review procedures.
KORU Medical Systems entered into an Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc. to secure the production of subassemblies, needle sets, and tubing products.
🚩 Red Flags
- Termination clause allows for termination upon bankruptcy or insolvency of the other party (standard but noted).
📋 Key Facts
- Agreement effective date: January 1, 2024; executed on November 19, 2025.
- The agreement amends and restates a previous contract dated November 11, 2020.
- Command Medical Products will manufacture subassemblies, needle sets, and tubing products to KORU's specifications.
- Agreement expires December 31, 2026, with automatic one-year renewal clauses.
- Includes provisions for pricing, rebates, and purchase commitments based on forecasts.
KORU Medical Systems, Inc. announced its third fiscal quarter financial results for the period ended September 30, 2025, and provided updated financial guidance for the full fiscal year ending December 31, 2025.
📋 Key Facts
- Reporting period: Third fiscal quarter ended September 30, 2025.
- Company issued a press release on November 12, 2025, regarding financial results and updated guidance.
- Management provided non-GAAP measures including 'adjusted EBITDA' and 'adjusted diluted EPS'.
- The filing includes an update to fiscal year 2025 guidance.
KORU Medical Systems, Inc. announced its second quarter 2025 financial results and updated its full-year fiscal 2025 guidance via a press release on August 6, 2025.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- The company issued an update to its financial guidance for the fiscal year ending December 31, 2025.
- Management highlighted non-GAAP measures including 'adjusted EBITDA' and 'adjusted diluted EPS'.
- A conference call was scheduled for August 6, 2025, at 4:30pm ET to discuss results.
KORU Medical Systems, Inc. reported the voting results from its 2025 Annual Meeting of Shareholders held on May 14, 2025. The meeting resulted in the successful election of seven directors and advisory/ratification approvals for executive compensation and independent auditors.
📋 Key Facts
- Annual Meeting held on May 14, 2025.
- Total shares voted: 36,949,703.
- Proposal 1: All seven director nominees (Fletcher, Cascella, French, Manko Jr., Matin, Tharby, and Wholihan) were elected.
- Proposal 2: Shareholders approved executive compensation on an advisory basis with 23,167,952 votes 'For'.
- Proposal 3: Ratified the appointment of Cherry Bekaert LLP as independent registered public accountants for fiscal year 2025.
KORU Medical Systems, Inc. announced its financial results for the first quarter ended March 31, 2025, and provided updated financial guidance for the full fiscal year ending December 31, 2025.
📋 Key Facts
- Report covers Q1 fiscal year ended March 31, 2025.
- Company issued an update to its full-year (FY) 2025 financial guidance.
- Management emphasized the use of non-GAAP measures including 'adjusted EBITDA' and 'adjusted diluted EPS'.
- Results were accompanied by a press release and a scheduled conference call on May 7, 2025.
KORU Medical Systems announced the immediate resignation of its Chief Commercial Officer, Kenneth Miller, effective April 3, 2025. The company is initiating a search for a successor and has appointed Rob Cannon to lead commercial operations in the interim.
🚩 Red Flags
- Immediate departure of a key executive (CCO) can create leadership instability and disrupt commercial momentum.
📋 Key Facts
- Kenneth Miller resigned as Chief Commercial Officer on April 3, 2025, to pursue a CEO role at a non-competing organization.
- Rob Cannon (VP of Sales for North America since Nov 2021) will lead commercial operations for the Core business temporarily.
- The company has engaged an executive search firm to find a new CCO.
- Company reiterated full year 2025 revenue guidance of $38.0-$39.0 million (originally issued March 12, 2025).
KORU Medical Systems entered into an amendment to its loan and security agreement with HSBC Ventures USA Inc. on March 31, 2025. The amendment extends the maturity dates of existing credit facilities and relaxes certain financial covenants.
🚩 Red Flags
- Relaxation of financial covenants (Adjusted Quick Ratio) suggests the company may have been at risk of breaching existing terms.
- The need for maturity extensions indicates a requirement for more time to meet repayment obligations or improve liquidity.
📋 Key Facts
- Amendment dated March 31, 2025, with HSBC Ventures USA Inc.
- Maturity of $5,000,000 revolving credit facility extended to December 31, 2026.
- Interest-only portion of the $5,000,000 term loan facility extended to October 1, 2026.
- Adjusted Quick Ratio covenant relaxed from a range of 1.25–1.50 down to 1.00–1.25.
KORU Medical Systems, Inc. announced its fourth quarter and full year 2024 financial results and provided financial guidance for the fiscal year ending December 31, 2025.
📋 Key Facts
- Reporting period: Fourth quarter and year ended December 31, 2024.
- Guidance provided: Financial guidance issued for the fiscal year ending December 31, 2025.
- Non-GAAP measures used: Management is utilizing Adjusted EBITDA and Adjusted EPS to communicate performance.
- Reporting date: March 12, 2025.
KORU Medical Systems, Inc. issued an 8-K to announce preliminary financial results for the fiscal quarter and year ended December 31, 2024. The company also released a new investor presentation via Regulation FD disclosure.
📋 Key Facts
- Preliminary financial results announced for Q4 and FY 2024 (ended Dec 31, 2024).
- Results are based on current estimates and remain subject to change pending final closing procedures.
- An investor presentation was released via the company's website as of January 13, 2025.
KORU Medical Systems, Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended September 30, 2024. The filing includes a press release and references non-GAAP financial measures such as Adjusted EBITDA and Adjusted EPS.
📋 Key Facts
- Reporting period: Fiscal quarter ended September 30, 2024.
- Filing date: November 13, 2024.
- The company is utilizing non-GAAP measures (Adjusted EBITDA and Adjusted EPS) to supplement GAAP results.
- Management held a conference call on November 13, 2024, to discuss the results.
KORU Medical Systems, Inc. announced the approval of a new Long-Term Incentive Program (LTIP) designed to incentivize executive and employee retention through equity-based awards. The program includes RSUs, PSUs, and stock options for key executives, including the CEO, CFO, CCO, and COO.
🚩 Red Flags
- Potential dilution through the issuance of new equity under the 2024 Omnibus Equity Incentive Plan.
📋 Key Facts
- The LTIP was approved by the Compensation Committee on August 15, 2024.
- Awards were granted to Linda Tharby (CEO), Thomas Adams (CFO), Kenneth Miller (CCO), and Christopher Pazdan (COO).
- Executive awards include Restricted Stock Units (RSUs), Performance Stock Units (PSUs), and Nonqualified Stock Options.
- The CEO's award structure is weighted differently: 25% RSUs, 50% PSUs, and 25% Options, compared to a 33/33/33 split for other executives.
- PSU vesting is tied to the Company's annual revenue for the fiscal year ending December 31, 2026.
- Options exercise price set at $2.33 per share (arithmetic mean of high/low prices on Nasdaq).
- CCO Kenneth Miller received a base salary increase to $385,000 and an increased bonus potential effective August 18, 2024.
KORU Medical Systems, Inc. issued an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024. The filing serves as a formal notice of the earnings release and accompanying conference call.
📋 Key Facts
- Financial results for the fiscal quarter ended June 30, 2024 were released on August 7, 2024.
- The company is utilizing non-GAAP financial measures including Adjusted EBITDA and Adjusted EPS to supplement GAAP reporting.
- A conference call was scheduled for August 7, 2024, at 4:30 pm ET to discuss the results.
KORU Medical Systems announced a leadership restructuring involving the appointment of Christopher Pazdan as the new Chief Operating Officer and the elimination of the Chief Technology Officer position, which will result in the departure of Brian Case.
🚩 Red Flags
- Elimination of the Chief Technology Officer (CTO) position may indicate a shift in corporate strategy or restructuring costs.
📋 Key Facts
- Christopher Pazdan appointed to newly-created COO position effective July 18, 2024.
- Pazdan's base salary is $350,000 with an annual bonus potential of up to 50% of base salary.
- The CTO position held by Brian Case will be eliminated effective September 16, 2024.
- Mr. Pazdan previously served as SVP, Operations at KORU and has extensive experience at Abbott Laboratories and Becton Dickinson.
KORU Medical Systems, Inc. announced the dismissal of its independent registered public accounting firm, McGrail Merkel Quinn & Associates, P.C., effective June 3, 2024. The company has simultaneously engaged Cherry Bekaert LLP as its new auditor for the fiscal year ending December 31, 2024.
🚩 Red Flags
- Auditor change (dismissal of existing firm) often triggers increased scrutiny from investors despite lack of reported disagreement.
📋 Key Facts
- Dismissal of McGrail Merkel Quinn & Associates, P.C. (MMQ) effective June 3, 2024.
- Engagement of Cherry Bekaert LLP as the new independent registered public accounting firm for FY2024.
- The company stated that MMQ's reports for fiscal years ended Dec 31, 2023, and Dec 31, 2022, did not contain adverse opinions, disclaimers, or qualifications.
- No disagreements regarding accounting principles, financial statement disclosure, or auditing scope were reported between the company and MMQ.
KORU Medical Systems, Inc. reported the voting results from its 2024 Annual Meeting of Shareholders held on May 9, 2024. All proposals, including director elections and auditor ratification, were approved by shareholders.
📋 Key Facts
- Annual Meeting held on May 9, 2024, with 38,339,108 total shares voted.
- All seven nominees for the Board of Directors were elected (including R. John Fletcher and Robert A. Cascella).
- Shareholders approved executive officer compensation on an advisory basis.
- McGrail Merkel Quinn & Associates, P.C. was ratified as independent registered public accountants for fiscal year 2024.
- The 2024 Omnibus Equity Incentive Plan was approved by shareholders.
KORU Medical Systems, Inc. issued an 8-K to announce the release of its financial results for the fiscal quarter ended March 31, 2024.
📋 Key Facts
- Financial results for the fiscal quarter ended March 31, 2024, were announced on May 1, 2024.
- The company is utilizing non-GAAP financial measures including Adjusted EBITDA and Adjusted EPS to supplement GAAP reporting.
- Management defines Adjusted EBITDA by adding back interest, taxes, depreciation, amortization, reorganization charges, discontinued product expenses, allowance for nonrealization of deferred tax assets, manufacturing initiative expenses, and stock-based compensation.
KORU Medical Systems' appeal against a European Union notified body (BSI) was unsuccessful, resulting in a recommendation that the company's certification cannot be continued due to technical documentation nonconformance. This poses a significant risk to the company's ability to market products within the EU.
🚩 Red Flags
- Loss of EU certification recommendation: This directly impacts the ability to sell medical devices in the European market, which is a critical revenue driver for micro-cap medtech companies.
- Regulatory setback: The failure of an appeal indicates significant hurdles in meeting EU regulatory standards (MDR/IVDR) regarding technical documentation.
📋 Key Facts
- On April 8, 2024, KORU Medical Systems' appeal against BSI's determination was upheld.
- BSI (the notified body in the EU) recommended that continued certification cannot be made following a review of technical documentation.
- The nonconformance is related to a prior audit by BSI.
- The company intends to address the nonconformance through the routine BSI assessment process.
KORU Medical Systems entered into a $10 million credit facility with HSBC Ventures USA Inc., consisting of a $5 million revolving credit line and a $5 million term loan. The agreement includes the issuance of stock purchase warrants to the lender as a condition of the term loan.
🚩 Red Flags
- Asset-backed debt: The loan is secured by a first-priority lien on substantially all company assets.
- Equity dilution: Issuance of stock purchase warrants to the lender as part of the financing terms.
- Restrictive covenants: Includes negative covenants restricting mergers, acquisitions, and dividend payments.
📋 Key Facts
- Total Credit Facility: $10,000,000 ($5M Revolver + $5M Term Loan).
- Lender: HSBC Ventures USA Inc.
- Security: First-priority lien on substantially all of the Company's assets.
- Revolver Terms: Matures Dec 31, 2025; interest at greater of Prime or 6.50%.
- Term Loan Terms: Matures Dec 1, 2028; interest-only through Dec 31, 2025.
- Warrant Issuance: 76,104 shares of common stock at an exercise price of $2.12 per share.
- Financial Covenant: Must maintain a minimum Adjusted Quick Ratio of 1.50 to 1.00.